A modification within the coding region of the associated mRNA transcript, and enhances its translation by relieving ribosome stalling. We show that genes regulated by METTL3 in this way are necessary for acute myeloid leukaemia. Together, these data define METTL3 as a regulator of a chromatinbased pathway that is necessary for maintenance of the leukaemic state and identify this enzyme as a potential therapeutic target for acute myeloid leukaemia.
A modification within the coding region of the associated mRNA transcript, and enhances its translation by relieving ribosome stalling. We show that genes regulated by METTL3 in this way are necessary for acute myeloid leukaemia. Together, these data define METTL3 as a regulator of a chromatinbased pathway that is necessary for maintenance of the leukaemic state and identify this enzyme as a potential therapeutic target for acute myeloid leukaemia.
To identify RNA-modifying enzymes that are necessary for the survival and proliferation of acute myeloid leukaemia (AML) cells, we performed two independent CRISPR screens. First, we performed an ex vivo genome-wide CRISPR dropout screen (Screen 1) using Cas9-expressing mouse primary leukaemia cells driven by a KMT2A-MLLT3 (also known as MLL-AF9) fusion gene and an Flt3 internal tandem duplication 6 (Fig. 1a ). This screen identified 1,550 dropout targets with a false discovery rate (FDR) of 0.25 (Supplementary Table 1 ), including 75 genes encoding possible RNA-modifying enzymes whose expression is necessary for growth of primary leukaemia cells (see Methods; Supplementary Table 2) .
Cas9-induced indel mutations cause stronger negative selection in dropout screens when critical functional domains are targeted 7 . Therefore, we constructed a custom domain-focused guide RNA (gRNA) library including the 75 RNA-modifying enzymes identified above (Screen 2). This identified, with high confidence, 46 potential RNA-modifying enzymes whose catalytic activity is required for leukaemia cell growth (Fig. 1b and Supplementary Table 2 ). Although the two screens were highly correlated overall, comparison between them highlights targets whose catalytic activity is specifically required for leukaemia cell growth (Extended Data Fig. 1a ).
Two Mettl gene family members, Mettl3 and Mettl16, scored very highly, whereas Mettl14 and Mettl1 showed substantial but lower negative selection. METTL3 and METTL14 form a complex that catalyses RNA adenosine N 6 -methylation 4 . METTL16 is also an m 6 A methyltransferase 8 . This modification is present in mRNAs 1 , premicroRNAs 2 and long non-coding RNAs 3 , and it affects mRNA stability 9,10 and translation
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. Notably, the m 6 A demethylase gene FTO, which is required for human leukaemia cell growth 12 , was not identified in Screen 1; this may be explained by the heterogeneous genetic background of human AML cell lines.
We validated our results using growth competition assays with individual gRNAs targeting the regions encoding for the catalytic domains of Mettl3 and Mettl16 (as in Screen 2) in mouse AML cells (Extended Data Fig. 1b) . Furthermore, negative selection of gRNAs targeting either early exons (as in Screen 1) or the catalytic domain of Mettl3 was validated in different mouse primary leukaemia cell lines (Extended Data Fig. 1c) . Finally, disruption of the catalytic domain of Mettl3 strongly suppressed primary mouse AML cell colony formation ( Fig. 1c and Extended Data Fig. 1d ). By contrast, targeting Mettl3 in non-transformed NIH3T3 and primary haematopoietic cells had no significant effect (Extended Data Fig. 1e , f). Our findings indicate that these genes are specifically essential for cell survival in AML and not for general cellular viability.
We next targeted METTL1, METTL3, METTL14 and METTL16 in ten human AML cell lines and ten cell lines from heterogeneous cancer types. All four METTLs showed negative selection in all AML cell lines tested (Extended Data Fig. 1g ), but displayed varying degrees of negative selection in non-AML tumours (Extended Data Fig. 2a ). These differences are not due to variable editing levels across cell lines (Extended Data Fig. 2b) .
Disruption of METTL3 reverses the myeloid differentiation block that is characteristic of AML in both mouse and human AML cells ( Fig. 1d and Extended Data Fig. 2c, d ). Increased expression of CD11b, a granulocytic differentiation marker 13 , occurred in all METTL3-domain-knockout cells analysed, consistent with METTL3 loss promoting AML cell differentiation. Strikingly, targeting the methyltransferase domain of METTL3 markedly impaired engraftment of human leukaemic cells into immunocompromised mice ( Fig. 1e and Extended Data Fig. 2e ), with grafted mice surviving significantly longer than controls (P = 0.0029; Fig. 1f ). An independent genetic approach, using human MOLM13 leukaemia cells harbouring inducible METTL3-specific short hairpin RNAs (shRNAs), was used to validate our findings. These cells showed near-complete loss of METTL3 mRNA and protein (Extended Data Fig. 3a , b) and markedly reduced proliferation (Fig. 1g ) upon induction of shRNAs by doxycycline. Similar results were obtained using the human AML cell line THP1 (Extended Data Fig. 3c ). Notably, ectopic expression of METTL3 (Extended Data Fig. 3d ) fully rescued the proliferation defect, whereas a catalytically inactive mutant failed to do so (Fig. 1h) , confirming that loss of growth was due to lack of METTL3 catalytic activity.
RNA sequencing (RNA-seq) of METTL3 knock-down (METTL3-KD) cells showed altered expression of transcripts, both upregulated (n = 167) and downregulated (n = 180; Extended Data Fig. 3e and Supplementary Table 3) . Gene ontology analysis of differentially expressed genes revealed downregulation of cell cycle pathway genes and upregulation of haematopoietic cell differentiation genes, mirroring our findings obtained using CRISPR-Cas9 and flow cytometry analyses (Extended Data Fig. 3f and Supplementary Table 4 ). These data demonstrate that METTL3 is required for leukaemic cell growth and that its inactivation induces differentiation of KMT2A-MLLT3-driven AML cells.
Next we investigated METTL3 expression in different cancer samples from The Cancer Genome Atlas (TCGA) 14 . The highest expression of METTL3 (but not METTL14) was identified in AML cells, diffuse large B-cell lymphoma and prostate adenocarcinoma cells (Extended Data  Fig. 4a ). Strikingly, these three cancer types correspond to the cell lines that are sensitive to METTL3 targeting (Extended Data Figs 1g, 2a) . Furthermore, overexpression of METTL3 increases proliferation in human AML cell lines (Extended Data Fig. 4b ). These observations are consistent with METTL3 playing an oncogenic role in AML.
Cytoplasmic signalling enzymes can directly regulate genes by binding chromatin 15 . We therefore tested whether METTL3 binds chromatin. We detected both METTL3 and its partner METTL14 associated with chromatin fractions from MOLM13 cells (Extended Data Fig. 4c ).
To identify genomic loci bound by METTL3 and/or METTL14, we performed chromatin immunoprecipitation (ChIP) using antibodies against METTL3, METTL14 and trimethylation of lysine 4 on histone H3 (H3K4me3). This identified 126 METTL3 and 119 METTL14 genomic peaks (Fig. 2a, Extended Data Fig. 4d and Supplementary  Table 5 ). Both METTL3 and METTL14 localized mainly to the transcriptional start sites (TSSs) of coding genes characterized by bimodal H3K4me3 peaks (for example, Fig. 2a, b and Extended Data Fig. 4e, f) . Unexpectedly, the two METTLs did not bind the same TSSs (Extended Data Figs 4g, 5a), suggesting that they have distinct roles on chromatin. Here, we focus on METTL3 and its functions. We validated several METTL3 peaks by ChIP with quantitative PCR (ChIP-qPCR) using two different METTL3-specific antibodies (Extended Data Fig. 5b, c) and confirmed that METTL3-KD led to reduction of the METTL3 ChIP signal at specific promoters ( Fig. 2c and Extended Data Fig. 5d ).
We interrogated sequences under METTL3 peaks for enriched motifs and identified the CCAAT box as the top hit (Extended Data  Fig. 6a ). This motif binds the NFYA-NFYB complex 16 , which associates with H3R2me2s (symmetric dimethyl-histone H3 (Arg2)) and the WD repeat protein WDR5 on active promoters 17 . Another significantly enriched METTL3 peak motif is that for the transcription factor KLF9 (P = 1 × 10 −4 ). Using existing ChIP with sequencing (ChIP-seq) datasets 5 , we observed a high correlation between METTL3 binding sites and all of these factors (NFYA-NFYB, H3R2me2s, WDR5 and KLF9; see Extended Data Fig. 6b ). METTL14 peaks showed no correlation with the same factors, except for WDR5 (Extended Data Fig. 6b ). Co-occupancy by all of these factors on 447 promoters overlaps with METTL3 binding (Extended Data  Fig. 6c, d ), but their combined predictive power for defining METTL3 bound sites is limited. letter reSeArCH
We then selected the genes that were most tightly co-expressed with METTL3 (top 2.5th percentile) in normal and cancer cell lines 18 . Eleven AML ENCODE ChIP-seq datasets are available for these co-expressed To test whether CEBPZ is involved in recruiting METTL3 to TSSs, we performed METTL3 ChIP-qPCR experiments after CEBPZ knockdown. Figure 2f and Extended Data Figure 7i show reduction of chromatin-bound METTL3 at several promoters in CEBPZ-KD cells. Thus, METTL3 and METTL14 are recruited to highly specific chromatin sites, with METTL3 localizing to TSSs with a well-defined signature of transcription factors and histone modifications. This suggests that METTL3 regulates the expression of mRNAs derived from its chromatin target genes.
Transcriptional profiling of METTL3-depleted cells showed that the levels of mRNAs transcribed from METTL3-bound genes were not affected (Extended Data Fig. 7j and Supplementary Table 3; odds ratio (OR) = 0.75; P = 1). Given that METTL3 catalytic activity is essential for AML cell growth (Fig. 1h) , we investigated post-transcriptional events that could be regulated by METTL3-mediated RNA methylation.
To identify RNAs methylated by METTL3 in AML cells, we performed RNA-immunoprecipitation linked to high throughput sequencing using an m A occurs within the coding regions of transcripts of METTL3-bound genes, in contrast to its distribution in the general transcriptome, where it is enriched within mRNA 3′ untranslated regions (UTRs) ( Fig. 3b and Extended Data Fig. 8d ).
To investigate whether promoter-bound METTL3 is required for m 6 A modification of associated transcripts, we measured m 6 A modification in these mRNAs following CEBPZ-KD, as this leads to loss of METTL3 at TSSs (Fig. 2f) . CEBPZ-KD reduced m 6 A in relevant mRNAs ( Fig. 3c and Extended Data Fig. 8e ). By contrast, no changes were observed in control mRNAs such as GAPDH. As expected, CEBPZ-KD did not affect mRNA levels of METTL3 chromatin targets or levels of METTL3 itself (Extended Data Fig. 8f) .
Analysis of the whole coding sequences of these transcripts revealed enrichment of a [GAG] n motif (Fig. 3d ). This motif, while common throughout coding transcripts, is significantly overrepresented amongst transcripts derived from METTL3-bound genes (P = 0.0098; Extended Data Fig. 8g) . Notably, the motif 's reading frame (+ 2) is preserved throughout transcripts derived from METTL3-bound genes (Fig. 3e) . Although the relevance of this motif remains unclear, its presence suggests that these GAG-rich transcripts require m 6 A modification for translational efficiency. We therefore performed ribosome footprinting (RFP) of control and METTL3-KD MOLM13 cells, to evaluate their translational output (Extended Data Fig. 9a-c) . Although mRNAs marked with m 6 A generally tended to show increased translational efficiency following METTL3-KD
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, transcripts derived from genes harbouring METTL3 on their promoter were translated less efficiently ( Fig. 3f and Supplementary Table 7) . We therefore mapped ribosomal pausing sites on mRNAs produced from METTL3-bound genes. P-site codon occupancy in these transcripts indicated that four codons-GAG, GAT, GAC, GAA (GAN codons)-are more occupied by ribosomes in METTL3-KD cells than in control cells (Fig. 3g and Extended Data Fig. 9d ). The same was not observed as a general feature throughout the transcriptome (Extended Data Fig. 9e, f) and is not due to general overrepresentation of GAN codons throughout transcripts (Extended Data Fig. 9g ).
To better characterize how METTL3 regulates translation, we focused on two genes encoding the transcription factors SP1 and SP2, which have promoters occupied by METTL3. The levels of SP1 and SP2 proteins are reduced upon METTL3 depletion (Fig. 4a ), but their mRNA levels are unaffected (Extended Data Fig. 10a ). Indeed, a similar reduction in SP1 protein levels is observed upon CEBPZ-KD (Extended Data Fig. 10b ). We next investigated how METTL3-KD affects the association of SP1 and SP2 mRNA with polysomes (Extended Data  Fig. 10c ). Upon METTL3 depletion, there was a specific shift of SP1 and SP2 transcripts towards lower molecular weight polysomes (Fig. 4b) , indicating less efficient translation, whereas there were no differences for control mRNAs (Extended Data Fig. 10d) .
The above results demonstrate that METTL3 affects translation of the mRNAs whose promoters it occupies. We next aimed to prove that recruitment of METTL3 to promoters is sufficient for this effect. For this, we used a reporter system (Fig. 4c) consisting of a plasmid harbouring GAL4 binding sites upstream of a constitutive promoter that expresses an SP2 (m 6 A peak)-luciferase mRNA fusion. We expressed the METTL3 wild-type catalytic domain, or an inactive point mutant 20 , in-frame with the GAL4 DNA-binding domain. Consistently, only recruitment of wild-type METTL3-GAL4 enhanced luciferase activity ( Fig. 4d and Extended Data Fig. 10e ), without affecting luciferase mRNA levels (Extended Data Fig. 10f ). These data corroborate the theory that promoter-bound METTL3 augments translation of its target genes.
Consistent with depletion of SP1 and SP2 protein in METTL3-KD cells, genes directly bound and regulated by these factors 5 were also generally downregulated in METTL3-depleted MOLM13 cells (Extended Data Fig. 10g ). Amongst these is the c-MYC oncogene, whose promoter is bound by both SP1 and SP2 (Extended Data Fig. 10h and Supplementary  Table 3 ). We tested whether loss of SP1 could explain the proliferation defect caused by METTL3 depletion. Figure 4e shows that ectopic overexpression of SP1 in METTL3-KD cells (Extended Data Fig. 10i ) rescues cell growth. Strikingly, CRISPR targeting of SP1 is lethal in cell lines that are sensitive to METTL3 inactivation, but not in other cell lines (Fig. 4f) . These observations suggest that the sensitivity of leukaemic cells to loss of METTL3 is dictated by the requirement of SP1 for cell growth.
Here we define a set of RNA-modifying enzymes that are necessary for AML leukaemia and identify a leukaemic pathway for the METTL3 RNA methyltransferase. In this pathway, METTL3 is stably recruited by CEBPZ to promoters of a specific set of active genes, resulting in m 6 A methylation of the respective mRNAs and increased translation. One important target is SP1, an oncogene in several cancers 21 , which regulates c-MYC expression 22 . Consistent with these findings, it has been reported that METTL3 can methylate its targets co-transcriptionally 23 .
METTL3 affects mRNA translation in numerous ways, including by promoting RNA loading onto ribosomes 24 and recruiting specific m 6 A reader proteins (for example, YTHFD1) 25 . The findings presented here provide substantial insight into the mechanisms through which METTL3 promotes post-transcriptional regulation of gene expression. Our data identify a new paradigm for selecting RNAs to be modified, namely the stable recruitment of the RNA-modifying enzyme to specific genomic loci. They also demonstrate a mechanism by which m 6 A can affect translation, namely relief of ribosome stalling at GAN codons of specific transcripts.
The pathway described here is critical for AML leukaemia, as three of its components are required for AML cell growth: (i) the m 6 A RNA methyltransferases METTL3; (ii) the transcription factor CEBPZ, which targets this enzyme to promoters; and (iii) SP1, whose translation is dependent upon the m 6 A modification by METTL3. Together, these observations define METTL3 enzymatic activity as a new candidate target for the treatment of AML.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. ITD/+ mice was used. Bone marrow cells were exposed to erythrocyte lysis (BD PharmLyse, BD Bioscience), followed by magnetic bead selection of Lin − cells using the Lineage Cell Depletion Kit (Miltenyi Biotec) according to the manufacturer's instructions. Lin − cells were cultured in X-VIVO 20 (Lonza) supplemented with 5% BIT serum substitute (Stem Cell Technologies), 10 ng ml −1 IL3 (Peprotech), 10 ng ml −1 IL6 (Peprotech) and 50 ng ml −1 of SCF (Peprotech). Retrovirus constructs pMSCV-MLL-AF9-IRES-YFP and pMSCV-MLL-ENL-IRES-Neo were used with package plasmid psi-Eco to produce retrovirus. 293T cells (Life Technologies) were cultured and prepared for transduction in 10-cm plates as described above. For virus production, 5 μ g of the above plasmids and 5 μ g psi-Eco packaging vector were transfected drop-wise into the 293T cells using 47.5 μ l TransIT LT1 (Mirus) and 600 μ l Opti-MEM (Invitrogen). Transduction of primary mouse cells was performed in 6-well plates as mentioned above. After transduction, cells were sorted for YFP (for KMT2A-MLLT3) or selected with neomycin (for KMT2A-MLLT1). Generation of genome-wide mutant libraries and screening. Ex-vivo CRISPR screens were performed using the previously reported WT Sanger genome-wide CRISPR library 6 , which uses five gRNAs for each of the 18,424 targeted genes. 3.0 × 10 7 cells were infected with a pre-determined volume of the genome-wide gRNA lentiviral supernatant that gave rise to 30% transduction efficiency measured by BFP expression. Two independent infections were conducted for the mouse primary AML cells. Two days after transduction, the cells were selected with puromycin at 1.5 μ g ml −1
. Genomic DNA extraction and Illumina sequencing of gRNAs were conducted as described previously 6 . For the primary mouse AML screen, 19-bp single-end sequencing was performed with the custom sequencing primer 5′ -TCTTCCGATCTCTTGTGGAAAGGACGAAACACCG-3′ . The number of reads for each guide was counted with an in-house script. Enrichment and depletion of guides and genes were analysed using the MAGeCK statistical package 27 by comparing read counts from each cell line with counts from matching plasmids as the initial population.
The 296 RNA enzyme list, which has been interrogated for dropouts, was compiled as follows: 171 SAM-binding proteins without known histone methyltransferase activity; 65 ATP-dependent helicases with reported RNA interaction in at least 3 out of 4 CLIP data sets [28] [29] [30] [31] ; 12 pseudouridylases; 48 annotated RNA enzymes not included in the previous lists (Supplementary Table 2 ). Lentiviral vector production and infection. For virus production, 293T cells were transfected with the appropriate lentiviral vector (PLKO.1 for shRNA, LRG and LentiCRISPR-v2 for CRISPR-Cas9) together with the packaging plasmids PAX2 and VSVg at a 1:1.5:0.5 ratio. Supernatant was harvested 48 and 72 h after transfection.
1 × 10 6 cells and viral supernatant were mixed in 2 ml culture medium supplemented with 8 μ g ml −1 (human) or 4 μ g ml −1 (mouse) polybrene (Millipore), followed by spinfection (60 min, 900g, 32 °C) and further incubated overnight at 37 °C. The medium was refreshed on the following day and the transduced cells were cultured further. Pooled domain-focused CRISPR gRNA construction. For the RNA enzyme domain-focused CRISPR screen, five gRNAs were designed to target the catalytic domain of each protein based on the NCBI database annotation. gRNAs were synthesized in a pooled format on an array platform (Twist Bioscience) and PCRcloned into a lentiviral gRNA expression vector (LRG, Addgene: 65656). To check the representation and identity of individual gRNAs within the lentiviral pool, a deep-sequence analysis was performed. This confirmed that 100% of the designed gRNAs were cloned in the LRG vector and the abundance of > 95% of the gRNA constructs was within fivefold of the mean.
Pooled gRNA screening, Miseq library construction and data analysis. Virus containing the domain-focused gRNA library against RNA modifying enzymes was generated as described above. A serial dilution of this virus in correlation with the GFP + cell population was used to estimate the viral titre multiplicity of infection (MOI). In the initial infected cell population, the total number of RN2c cells corresponded to an approximately one thousand-fold representation of each gRNA. To ensure that a single gRNA was transduced per cell, the viral volume for infection corresponded to an MOI of approximately 0.4-0.5. At 2 days post-infection, a portion of the RN2c cells was harvested and used as a reference time point. At the end point of the negative selection experiment, a portion of the RN2c cells was harvested again and saved for gRNA abundance quantification through deep sequencing analysis.
The gRNA cassette MiSeq deep sequencing library was constructed using a similar method as previously described 7 . Genomic DNA was extracted using QiAamp DNA mini kit (Qiagen 51304), following the manufacturer's protocol. In order to maintain approximately one thousand-fold gRNA library representation, 25 parallel PCR reactions were performed to amplify the gRNA cassette using the 2× High Fidelity Phusion Master Mix (Thermo Scientific F-548). PCR products were subjected to Illumina MiSeq library construction and sequencing. First, the PCR product was end repaired with T4 DNA polymerase (New England BioLabs, NEB), DNA polymerase I (NEB), and T4 polynucleotide kinase (NEB). Then, an A overhang was added to the end-repaired DNA using Klenow DNA Pol Exo-(NEB). The A-overhang DNA fragment was ligated with diversity-increased barcoded Illumina adaptors followed by seven pre-capture PCR cycles. The barcoded libraries were pooled at an equal molar ratio and subjected to massively parallel sequencing through a MiSeq instrument (Illumina) using paired-end 150-bp sequencing (MiSeq Reagent Kit v2; Illumina MS-102-2002).
The sequence data were de-barcoded and trimmed to contain only the gRNA sequence, and subsequently mapped to the reference gRNA library without allowing any mismatches. The read counts were calculated for each individual gRNA. To calculate the relative abundance of each gRNA, the read counts of each gRNA were divided by the total read counts of the pooled gRNA library. Validation of the catalytic domain-specific screen. RN2C cells or NIH3t3 mouse fibroblast cells were infected with LRG lentiviral vectors expressing GFP and a single gRNA targeting the catalytic domain of the indicated RNA enzymes and controls. The percentage of GFP + cells was measured at day 2 after infection as a baseline by flow cytometry. The percentage of GFP + cells was measured again at day 10 and day 12 for RN2C or NIH3T3 cells, respectively. Three gRNAs from Screen 2 were used for each target and one gRNA for the rosa26 locus as a negative control. The gRNA sequences are listed in the Supplementary Information. The data were analysed using Flowjo software. gRNA competition. gRNA competition assays were performed using single and dual gRNA vectors as described previously 2 . For the validation of individual target genes, one gRNA was derived from the CRISPR library used in the screens and another gRNA was designed using WTSI Genome Editing website (http:// www.sanger.ac.uk/htgt/wge/). Viral supernatants were collected 48 h after transfection. All transfections and viral collections were performed in 24-well plates and transduction was performed as mentioned above. For gRNA-BFP competition assays, flow cytometry analysis was performed on 96-well plates using a LSRFortessa instrument (BD). Gating was performed on live cells using forward and side scatter, before measuring of BFP + cells. The gRNA sequences are listed in the Supplementary Information.
Efficiency of genome editing in the pool of sgRNA-targeted cells was evaluated by tracking of indels by decomposition (TIDE) 32 . Replating assays. For re-plating assays, 5,000 lineage negative cells and primary murine AML cells expressing Cas9 were plated in three wells of a 6-well-plate of M3434 methylcellulose (Stem Cell Technologies) after infection with lentiviral vectors expressing gRNAs targeting the catalytic domain of METTL3 or empty vectors. The colonies were counted 7 days later and a further 5,000 cells re-seeded and re-counted after a week until no colonies were observed (for the wild type) or until the third replating (for primary mouse AMLs). Flow cytometry analyses of AML cells. Cas9-expressing cells were transduced with gRNA vectors targeting the catalytic domain of METTL3 or empty vectors and stained with anti-mouse CD11b PE/Cy5 (Biolegend, 101210) and anti-human CD11b PE (eBiosciences, 9012-0118). Data were analysed using LSRFortessa (BD) and FlowJo. Mouse whole-body bioluminescent imaging. For in vivo experiments, MOLM13 cells expressing Cas9 were transduced with a firefly luciferase-expressing plasmid (System Biosciences). After propagation, the cells were transduced with a lentivirus (either empty or expressing Mettl3 gRNA; day 0) and selected with puromycin from day 2 to day 5. At day 5 post-transduction, the cells were suspended in fresh medium without puromycin. At day 6, 1 × 10 5 cells were transplanted into female 6-week old Rag2
−/− Il2rg −/− mice by tail-vein injection. At day 14 post-transplant, letter reSeArCH the tumour burdens of the animals were detected using IVIS Lumina II (Caliper) with Living Image version 4.3.1 software (PerkinElmer). In brief, 100 μ l of 30 mg ml -1 d-luciferin (BioVision) was injected into the animals intraperitoneally. Ten minutes after injection, the mice were maintained in general anaesthesia by isoflurane and put into the IVIS chamber for imaging. The detected tumour burdens were measured and quantified by the same software. Mice were culled when the tumour burden was 10 8 photons per second or higher. The welfare of diseased mice was assessed blindly by qualified animal technicians from the Sanger mouse facility. All animal studies were carried out in accordance with the Animals (Scientific Procedures) Act 1986, UK and approved by the Ethics Committee at the Sanger Institute. Randomization and blinding were not applied. No statistical methods were used to predetermine sample size. Generation of conditional knock-down cells. MOLM13 or THP1 cells (5 × 10 5 ) were infected as described above using PLKO-TETon-Puro lentiviral vectors expressing shRNAs against the coding sequence of human METTL3, CEBPZ or a scrambled control. Twenty-four hours after spinfection, the cells were replated in fresh medium containing 1 μ g ml −1 of puromicin and kept in selection medium for 7 days. shRNA was induced by treatment with 200 ng ml −1 doxycycline for the indicated times. The shRNA sequences are listed in the Supplementary Information. Proliferation assays. MOLM13 and THP1 control or METTL3-KD cells (5 × 10 4 ; 4 days after doxycycline induction) were seeded in 2 ml complete RPMI medium and counted 4 days after plating using the Countess II cell counter. For SP1 rescue experiments, the number of doxycycline-treated cells was normalized to their untreated counterparts. Rescue experiments. cDNA was obtained by reverse transcription of MOLM13 cell RNA with Supercript III (ThermoFisher Scientific), then the SP1 full-length coding sequence was amplified by PCR and cloned into pHIV-ZsGreen plasmid (Addgene 18121) by Gibson assembly (Gibson Assembly Cloning Kit, NEB), using the HpaI site.
MOLM13 cells were transduced with the lentiviral constructs, then GFP + cells were isolated by flow cytometry sorting after 5 days and employed in proliferation assays as descripted in the previous section.
For rescue experiments with either active or catalytically mutant METTL3, pcDNA3/Flag-METTL3 plasmid (Addgene 53739) was mutagenized at the positions D394A (GAC/GCC) and W397A (TGG/GCG) as described 33 with QuikChange II Site-Directed Mutagenesis Kit (Stratagene).
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Cas9/+ cells were transduced with an empty or domainspecific Mettl3 gRNA lentiviral vector and selected with puromycin until day 5 post-transduction. Then cells were electroporated in Buffer R (Invitrogen) with the plasmids encoding wild-type METTL3, catalytically inactive METTL3 or an empty vector as a control. In each replicate, 150,000 cells were electroporated with 500 ng of each plasmid and plated in triplicate at 50,000 cells per well in a 6-well plate. Electroporation was performed using the Neon Transfection System (Thermo Fisher Scientific) as previously described 34 . Three days after electroporation (day 8), live cells were measured per well per condition. METTL3 overexpression and proliferation experiments. AML cells were electroporated in Buffer R (Invitrogen) with plasmids encoding wild-type METTL3 or an empty vector as a control. In each replicate, 200,000 cells were electroporated with 500 ng of each plasmid and plated in triplicate at 50,000 cells per well in a 6-well plate. Two days after electroporation (day 3), live cells were measured per well per condition. Chromatin immunoprecipitation. Chromatin immunoprecipitation was performed as previously described 35 . First MOLM13 cells were cross-linked with 0.5% formaldehyde for 10 min. 20 × 10 6 cells were used for each immunoprecipitation with 3 μ g of specific antibodies or IgG. Immunoprecipitated DNA was purified with ChIP DNA Clean & Concentrator Columns (Zymo) and either amplified for massive parallel sequencing or analysed on an ABI 7900 real-time PCR machine, Fast SybrGreen PCR mastermix according to the manufacturer's instructions. Primer sequences are listed in the Supplementary Information. ChIP sequencing. For the METTL3, METTL14, H3K4me3 and IgG ChIP-seq experiments, 5, 5, 2 and 3 independent biological replicates were used, respectively. Single-end 50-bp libraries were prepared using the Bioo Scientific NEXTflex ChIPSeq kit according to the manufacturer's recommendations. Reads were sequenced using HiSeq 1500 and multiplexed reads were split on the basis of their barcodes using Illumina Basespace. Reads were trimmed to remove the TruSeq adaptor using trim_galore (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore) with parameters '-q 0 -a AGATCGGAAGAGCACACGTCTGAACTCCAGTCACphred33-fastqc' . Read quality was assessed using FastQC. Ribosomal contamination was removed by first mapping the reads to hg38 rDNA sequences using bwa 36 (default parameters), and then removing all reads that mapped. Trimmed non-ribosomal reads were mapped to the hg38 genome using bwa with parameters '-n 3 -k 2 -R 300 -t 4' . Multiple reads mapping to a single genomic locus were treated as PCR duplicates, and were removed using samtools rmdup 37 . Mapped reads were filtered to remove reads mapping to more than one unique genomic locus (multihits) by keeping only reads with flag XT:A:U in the output bam file from bwa. Reads were further filtered to remove those with mapping quality less than 20 using samtools. Genome coverage bedgraph files were generated using genomeCoverageBed from the bedtools 38 suite of tools. Coverage files were converted to bigwig format using bedGraphToBigWig. Peaks were called against input sample using MACS2 using default parameters 39 . Peaks from all replicates were merged to give a master list of potential binding loci per condition, and read count (normalized by overall read depth of the library) for each replicate was calculated using the GenomicRanges package in R 40 . Peaks were treated as potential binding loci if all replicates showed normalized score greater than 1 and did not overlap a peak called in the IgG. Genomic annotation of ChIP peaks and reads and gene set operations were performed using the R packages ChIPseeker 41 and VennDiagram
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, respectively. HOMER tool suite 43 was used for DNA motif discovery coupled with hypergeometric enrichment calculations (or binomial) to determine motif enrichment. m 6 A RNA immunoprecipitation and sequencing. Total RNA was isolated from MOLM13 control or METTL3-KD cells (two independent biological replicates for each shRNA) eight days after doxycycline administration using the RNAeasy midi kit (Quiagen). Successively polyA + RNA was purified from 300 μ g total RNA using the NEBNext Poly(A) mRNA Magnetic Isolation Module (New England Biolabs). 500 ng of polyA + purified RNA was used for each immunoprecipitation reaction. m 6 A RNA immunoprecipitation was performed using the Magna MeRIP m 6 A kit (Millipore) according to the manufacturer's instructions.
Single-end 50-bp stranded libraries were prepared using the Bio Scientific NEXTflex Rapid Directional RNA kit according to the manufacturer's recommendations. Reads were sequenced using HiSeq 4000 and multiplexed reads were split on the basis of their barcodes using Illumina Basespace. Reads were trimmed to remove the TruSeq adaptor using trim_galore with parameters '-q 0 -a AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC-phred33-fastqc' .
Read quality was assessed using FastQC. Ribosomal contamination was removed by first mapping the reads to hg38 rDNA sequences using bwa (default parameters), and removing all reads that mapped. Trimmed non-ribosomal reads were mapped to the hg38 genome using Tophat2 with parameters '-no-coveragesearch-max-multihits 300-report-secondary-alignments-read-mismatches 2' . Gene annotations from Ensembl v86 were used to direct transcript alignment. Mapped reads were filtered to remove those mapping to more than one unique genomic locus (multihits) by keeping only reads with flag NH:i:1 in the output bam file from Tophat. Reads were further filtered to remove the ones with mapping quality less than 20 using samtools. Genome coverage bedgraph files were generated for forward and reverse strand reads using genomeCoverageBed from the bedtools suite of tools. Coverage files were converted to bigwig format using bedGraphToBigWig. Transcript assembly was performed using cufflinks2 and a single transcript database was generated using cuffmerge 44 . Statistical analysis of differentially methylated peaks in control and METTL3-KD cells was performed using the R package MeTDiff 45 . Metagene plots were generated by RNAModR package (https://github.com/mevers/RNAModR), and m 6 A motifs were analysed according to published protocols 46 . To evaluate the statistical significance of [GAG] n motif enrichment, individual motif occurrences were searched throughout the human transcriptome with FIMO program (MEME suite 47 ). Ribosome profiling. Ribosome profiling was carried out using the Illumina TruSeq Ribo Profiler (Mammalian) kit. 5 × 10 7 MOLM13 control (two pooled independent biological replicates) or METTL3-KD cells (two pooled independent biological replicates for each shRNA) were treated 5 or 8 days after doxycycline induction with 0.1 mg ml −1 of cycloheximide for 1 min and the RPF fraction of mRNA was isolated following the manufacturer's instruction. Ribosomal RNA was removed using the Illumina Ribozero Kit.
Single-end 50-bp stranded libraries were prepared following the manufacturer's recommendations. Reads were sequenced using HiSeq 1500 and multiplexed reads were split on the basis of their barcodes using Illumina Basespace. Reads were trimmed to remove the TruSeq adaptor using trim_galore with parameters '-q 0 -a AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC-phred33-fastqc' . Read quality was assessed using FastQC. Ribosomal contamination was removed by first mapping the reads to hg38 rDNA sequences using bwa (default parameters), and removing all reads that mapped. Trimmed non-ribosomal reads were mapped to the hg38 genome using Tophat2 with parameters '-no-coverage-search-maxmultihits 300-report-secondary-alignments-read-mismatches 2' . Gene annotations from Ensembl v86 were used to direct transcript alignment. Mapped reads were filtered to remove those mapping to more than one unique genomic locus (multihits) by keeping only reads with flag NH:i:1 in the output bam file from Tophat. Reads were further filtered to remove the ones with mapping quality less than 20 using samtools. Genome coverage bedgraph files were generated for forward and reverse strand reads using genomeCoverageBed from the bedtools suite of tools. Coverage files were converted to bigwig format using bedGraphToBigWig.
letter reSeArCH
Transcript assembly was performed using cufflinks and a single transcript database was generated using cuffmerge. Statistical analysis of differentially translated genes in control and METTL3-KD cells was performed using the R package xtail 48 . In order to estimate the offset value relative to the read start required to localize the position of P-sites (in our case ~ 12 nt, as already described in the literature 49 ), we employed the function psite of the plastid Python library 49 . Polysome fractionation. 5 × 10 7 MOLM13 control (two pooled independent biological replicates) or METTL3-KD cells (two pooled independent biological replicates) were treated 8 days after doxycycline induction with 0.1 mg ml −1 cycloheximide for 5 min at 37 °C, then they were lysed and polysomes were fractionated on a sucrose gradient as described 50 . Relative RNA abundance in each fraction was then quantified by RT-qPCR. RNA sequencing. Input samples from the m 6 A RNA immunoprecipitation and riboprofiling experiments were combined to give a set of transcriptional profiling samples to treat as an RNA-seq experiment (control n = 4, METTL3-KD n = 6). Gene counts were calculated at the transcript level for the combined transcript database from cuffmerge using summarizeOverlaps from the GenomicAlignments 40 package in R using a generalized linear model fit that takes into account possible batch effects of the two distinct experiments. Differential gene expression analysis was conducted using DESeq2 51 . Differentially expressed genes were identified as those with RPKM greater than 1 for wild-type or knockdown showing differential expression greater than twofold (up or down) with a Benjamini-Hochberg corrected P value less than 0.05 unless stated otherwise.
Gene set enrichment analysis was performed using the R package GAGE 52 . Construction of the engineered translation reporter system. A DNA sequence carrying ten GAL4 recognition motifs (or a scrambled version of the same sequence) was in vitro synthesized and cloned into a pMirGlo plasmid (Promega) upstream of the constitutive PGK promoter by cutting with BglII and ligating with T4 DNA ligase (NEB). The sequence of SP2 known to harbour the m 6 A peak and the [GAN] n motif was amplified by PCR and subcloned in frame at the N terminus of firefly luciferase by Gibson assembly (Gibson Assembly Cloning Kit, NEB), using the ApaI site.
To generate the GAL4-METTL3(CD) construct, the CREB coding sequence in plasmid pcDNAI-GAL4-CREB-S133A (Addgene 46770) was swapped with the METTL3 catalytic domain obtained by plasmid pcDNA3/Flag-METTL3 (Addgene 53739) using restriction enzymes XbaI and EcoRI. Wild-type METTL3 was mutagenized at the positions D394A (GAC/GCC) and W397A (TGG/GCG) as described 33 with the QuikChange II Site-Directed Mutagenesis Kit (Stratagene). Cloning primer sequences are listed in the Supplementary Information. Luciferase assay. 293T cells were co-transfected with the GAL4-METTL3 construct and UAS-SP2-Luc or SCR-SP2-Luc vectors expressing the Renilla luciferase as transfection control. Twenty-four hours after transfection, the firefly and Renilla luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega) on CLARIOstar microplate reader (BMG Labtech).
Alternatively, transfected cells were lysed and total RNA extracted using the Qiagen RNAeasy Mini kit according to the manufacturer's instructions. Western blotting. Western blotting was performed as previously described 53 . For the isolation of nuclei from the cytoplasmic fraction, cells were incubated in hypotonic buffer (20mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl 2 ,) and the cytoplasmic membranes disrupted by adding 0.5% NP40. Pelleted nuclei were successively lysed in IPH buffer (50mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40) for 10 min on ice. Nucleoplasmic and chromatin fractions were separated by 15 min centrifugation at 4 °C. The chromatin fraction was resuspended and sonicated in Laemmli buffer before loading on SDS-PAGE. RT-qPCR. Total RNA from MOLM13, THP1 or 293T cells was purified using the RNAeasy mini kit according to the manufacturer's instructions. One microgram of purified total RNA was retrotranscribed using the high-capacity cDNA reverse transcription kit (Applied Biosystems). The levels of specific RNAs were measured using an ABI 7900 real-time PCR machine and Fast SybrGreen PCR mastermix according to the manufacturer's instructions. Firefly luciferase levels were normalized on Renilla luciferase levels while METTL3 mRNA levels were normalized on ACTB mRNA. To quantify polysome fractionation and m letter reSeArCH showing decreased replating ability. CFU: colony-forming units; * * * P < 0.001, t-test. The mean + s.d. of three independent experiments is shown. e, Average ratio of the percentage of GFP-positive NIH-3T3 mouse fibroblasts between day 2 and day 12 after infection with lentiviral vectors expressing GFP and individual gRNAs against the indicated targets. The mean ± s.e.m. depletion of three different gRNAs against the catalytic domain of the targets is shown. Rpa is a positive control. f, Colony formation assay of lineage-negative haematopoietic Cas9-expressing cells targeting Mettl3 (catalytic domain-specific; right) or control. * * * P < 0.001; t-test. The mean + s.d. of three independent experiments is shown. g, Competitive co-culture assay showing negative selection of BFP + AML cell lines upon targeting of METTL3, METTL1, METTL14 and METTL16 by CRISPR-Cas9 using two independent gRNAs for each target. Cells were transduced with lentiviruses expressing BFP and four different gRNAs targeting the 5′ exons or the catalytic domain of each target and the BFP-positive fraction was compared with the non-transduced population. Results were normalized to those at day 4 for each gRNA. The mean + s.d. of two independent infections is shown. 
